Masatoshi Kudo

Research interests

Publications

• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)01796-8

• Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

  NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2100070

• Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

  Journal of Hepatology · 2021 · https://doi.org/10.1016/j.jhep.2021.11.030

• NASH limits anti-tumour surveillance in immunotherapy-treated HCC

  Nature · 2021 · https://doi.org/10.1038/s41586-021-03362-0

• Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1915745

• Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

  Journal of Clinical Oncology · 2020 · 10.1200/jco.20.00808

• Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

  JAMA Oncology · 2020 · 10.1001/jamaoncol.2020.4564

• Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

  Gut · 2019 · 10.1136/gutjnl-2019-318934

• Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(18)30937-9

• Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

  Journal of Clinical Oncology · 2019 · 10.1200/jco.19.01307

• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)30207-1

• Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30351-6

• Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31046-2

• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

  Hepatology International · 2017 · 10.1007/s12072-017-9799-9

• A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.

  PubMed · 2017 · https://doi.org/10.1159/000462153

• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)32453-9

• WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver

  Ultrasound in Medicine & Biology · 2015 · 10.1016/j.ultrasmedbio.2015.03.007

• Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00198-9

• Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

  Liver International · 2015 · 10.1111/liv.12818

• WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 1: Basic Principles and Terminology

  Ultrasound in Medicine & Biology · 2015 · 10.1016/j.ultrasmedbio.2015.03.009

• Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00050-9

• Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.45.8372

• Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.48.4410

• Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2012

  Ultrasound in Medicine & Biology · 2012 · 10.1016/j.ultrasmedbio.2012.09.002

• Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version

  Digestive Diseases · 2011 · 10.1159/000327577

• Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

  Hepatology International · 2010 · 10.1007/s12072-010-9165-7

Current projects

No projects listed.